BioLineRx Pivots to GLIX1: A Novel DNA-Repair Targeting Molecule Takes Center Stage in Glioblastoma

Small-cap biotech shifts from commercialized APHEXDA royalties to an early-stage pipeline bet on a first-in-class oral GBM therapy.

BLRX · Earnings Call · 2026-05-27

A Micro‑Cap Pivot

BioLineRx has long been a story of commercial execution — its sole marketed drug, APHEXDA (motixafortide), out‑licensed to Ayrmid Pharma, now contributes a trickle of royalties. But the Q1 2026 call marks a decisive pivot: the company is now betting its future on glioblastoma through a novel asset, GLIX1, obtained from Hemispherian. The shift is evident in the conversational gravity: the prepared remarks devote more attention to GLIX1 than to the cash‑generating APHEXDA. The company’s history of hunting for early‑stage assets, as repeated in prior calls, has now produced a concrete program. In August 2025, the CEO said: “We're looking for early stage. We're looking in our sweet spot, our wheelhouse, which is early clinical stage assets from IND through Phase I.” — Philip A. Serlin, Chief Executive Officer · 2025-08-14 That search has now yielded GLIX1.

GLIX1: The New Bet

GLIX1 is an oral small molecule that restores TET2 activity, selectively targeting DNA damage repair in cancer cells. The most compelling feature for GBM is its ability to cross the blood‑brain barrier — blood brain barrier penetration is a critical differentiator in a disease with few effective biologics. The company has initiated a Phase I/IIa first‑in‑human trial, and the first patient was dosed at NYU Langone. Three renowned academic centers (NYU, Northwestern, Moffitt) are participating. The preclinical data announced just before the call is striking. As CEO Phil Serlin put it: “we were very excited to announce just last week new data demonstrating that GLIX1 achieved robust dose‑dependent tumor growth inhibition and survival benefit in several studies in 2 orthotopic cell‑derived xenograft or CDx models in GBM.” — Philip Serlin, Chief Executive Officer · 2026-05-27 Even more notable, in a temozolomide‑resistant patient‑derived xenograft model, GLIX1 showed robust antitumor effect while temozolomide had none — a direct challenge to the current standard of care, which has been unchanged for over two decades.

We view this as a wide open market with few competitors.
Philip Serlin, Chief Executive Officer · 2026-05-27

The company also plans to combine GLIX1 with PARP inhibitors, a strategy supported by synergistic effects in cell lines across multiple cancers. Two abstracts at ASCO highlight the mechanistic rationale. The enthusiasm from investigators is high, as echoed in the March 2026 call: “There is real enthusiasm from the investigators participating in the study.” — Ella Sorani, Unknown · 2026-03-23

The Rest of the Portfolio

Beyond GLIX1, the company continues to support motixafortide in pancreatic cancer (PDAC) via the Columbia University‑led CheMo4METPANC trial. Enrollment is tracking, and a prespecified interim futility analysis is expected later this year when 40% of PFS events occur. However, the CEO acknowledged that new data from Revolution Medicines could alter the PDAC landscape, forcing a reevaluation of how CXCR4 inhibition fits as an adjunctive strategy. APHEXDA sales, managed by Ayrmid, are growing: $2.5M in Q1 2026 vs $1.4M a year ago, translating to $0.5M in royalty revenue for BioLineRx. The company also holds rights to develop motixafortide in sickle cell disease, where the standard of care G‑CSF is contraindicated. “This includes the evaluation of motixafortide in sickle cell disease.” — Philip Serlin, Chief Executive Officer · 2026-05-27

Financial Reality

The pivot comes at a cost. Revenue is minimal ($0.5M), while R&D expenses rose to $2.5M, driven by GLIX1. Net loss for the quarter was $2.6M, swinging from a $5.1M net income a year ago (which benefited from a nonoperating warrant adjustment of $7.6M). Cash stands at $17.4M, sufficient into the first half of 2027 — but that assumes no additional clinical failures or expansion costs. “Net loss for the quarter ended March 31, 2026, was $2.6 million compared to net income of $5.1 million for the quarter ended March 31, 2025.” — Mali Zeevi, Chief Financial Officer · 2026-05-27 The shift in keyword trajectory is stark. In 2025, the top themes were “cell mobilization” and “Sickle Cell”; now they are “Phase I/IIa” and “treatment paradigm” — Phase I/IIa is the new anchor. This is a genuine strategic pivot from a commercial royalty‑collector to an early‑stage clinical developer, betting that GLIX1’s novel mechanism can succeed where decades of GBM therapies have failed. For a micro‑cap with a $12M market cap, the upside (if GLIX1 shows activity) is enormous, but so is the risk of failure. The company is essentially a one‑horse race now, and that horse hasn’t even left the gate in terms of clinical efficacy data. The next catalytic milestones — Phase I data in 2027, ASCO abstracts now, and the PDAC interim — will determine whether this pivot was prescient or premature.